EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (START) study

Alessandro Cozzi-Lepri iD, David Dunn, Anna Tostevin, Rasmus L Marvig, Marc Bennedbaek, Shweta Sharma, Michael J Kozal, Mark Gompels iD, Angie N Pinto iD, Jens Lundgren, John D Baxter iD, INSIGHT START Study Group

HIV Medicine · 2024

DOI: 10.1111/hiv.13556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2024. Verfasst von Alessandro Cozzi-Lepri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health, UCL, London, UK. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents, HIV Seropositivity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The main objective of this analysis was to evaluate the impact of pre‐existing drug resistance by next‐generation sequencing (NGS) on the risk of treatment failure (TF) of first‐line regimens in participants enrolled in the START study.

Methods

Stored plasma from participants with entry HIV RNA >1000 copies/mL were analysed using NGS (llumina MiSeq). Pre‐existing drug resistance was defined using the mutations considered by the Stanford HIV Drug Resistance Database (HIVDB v8.6) to calculate the genotypic susceptibility score (GSS, estimating the number of active drugs) for the first‐line regimen at the detection threshold windows of >20%, >5%, and >2% of the viral population. Survival analysis was conducted to evaluate the association between the GSS and risk of TF (viral load >200 copies/mL plus treatment change).

Results

Baseline NGS data were available for 1380 antiretroviral therapy (ART)‐naïve participants enrolled over 2009–2013. First‐line ART included a non‐nucleoside reverse transcriptase inhibitor (NNRTI) in 976 (71%), a boosted protease inhibitor in 297 (22%), or an integrase strand transfer inhibitor in 107 (8%). The proportions of participants with GSS 20%, 10% for >5%, and 17% for the >2% thresholds, respectively. The adjusted hazard ratio of TF associated with a GSS of 0–2.75 versus 3 in the subset of participants with mutations detected at the >2% threshold was 1.66 (95% confidence interval 1.01–2.74; p = 0.05) and 2.32 (95% confidence interval 1.32–4.09; p = 0.003) after restricting the analysis to participants who started an NNRTI‐based regimen.

Conclusions

Up to 17% of participants initiated ART with a GSS

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Anti-HIV AgentsHIV SeropositivityHumansReverse Transcriptase InhibitorsHigh-Throughput Nucleotide SequencingViral LoadDrug Resistance, Viral

Stichwörter der Autor:innen

HIV drug resistanceantiretroviral therapyhuman immunodeficiency virus (HIV)next generation sequencing

Substanzen

Anti-HIV AgentsReverse Transcriptase Inhibitors

Autor:innen und Institutionen

  • Institute for Global Health, UCL, London, UK.
  • Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Virus Research and Development Laboratory, Virus and Microbiological Special Diagnostics, Statens Serum Institute, Copenhagen, Denmark.
  • Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Stanford University, Palo Alto, California, USA.
  • North Bristol NHS Trust, Bristol, UK.

ORCID-Profile: Alessandro Cozzi-Lepri, Mark Gompels, Angie N Pinto, John D Baxter

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Cozzi-Lepri, A., Dunn, D., Tostevin, A., Marvig, R. L., Bennedbaek, M., Sharma, S., Kozal, M. J., Gompels, M., Pinto, A. N., Lundgren, J., Baxter, J. D., & INSIGHT START Study Group (2024). Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (START) study. HIV Medicine. https://doi.org/10.1111/hiv.13556

Vancouver

Cozzi-Lepri A, Dunn D, Tostevin A, Marvig RL, Bennedbaek M, Sharma S, et al. Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (START) study. HIV Medicine. 2024. doi:10.1111/hiv.13556

BibTeX
@article{CozziLepri2024,
  author = {Cozzi-Lepri, Alessandro and Dunn, David and Tostevin, Anna and Marvig, Rasmus L and Bennedbaek, Marc and Sharma, Shweta and Kozal, Michael J and Gompels, Mark and Pinto, Angie N and Lundgren, Jens and Baxter, John D and INSIGHT START Study Group, INSIGHT START Study Group},
  title = {Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (START) study},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13556}
}
Kostenlos starten →